We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), in connection with its proposed merger with Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum Pharmaceuticals”).

Weiss Law is investigating whether (i) Assertio’s board acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration is fair to Assertio’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.